Purdue Pharma filed for Chapter 11 bankruptcy and agreed to pay between $10 and $12 billion to settle the drug manufacturer’s involvement in the health-care crisis.

OxyContin maker Purdue Pharma LP reached a tentative agreement with some plaintiffs to resolve litigation over the company’s alleged role in fueling the U.S. opioid crisis and plans to tussle with states opposing the settlement offer in bankruptcy proceedings, people familiar with the matter said.

Days after agreeing to pay nearly $225 million in additional fines to the U.S. government for fraudulent marketing schemes to boost sales of the opioid Subsys, Insys Therapeutics filed for bankruptcy.

Enumeral Biomedical filed for bankruptcy protection and is selling its assets to Xoma Corporation for $1.6 million.

A lawsuit brought against beleaguered blood-testing company Theranos alleges the company committed fraud by faking its blood-testing demonstrations.

Following its emergence from Chapter 11 bankruptcy protection, KaloBios is in the process of reacquiring company shares owned by its disgraced former CEO.

Two months after filing for 11 bankruptcy, Bind Therapeutics accepted a “stalking horse” bid from Pfizer.

KaloBios Pharmaceuticals has emerged from Chapter 11 bankruptcy and acquired the rights from Savant Neglected Diseases to develop benznidazole for treating Chagas disease.

May 2, 2016 By Alex Keown, BioSpace.com Breaking News Staff   CAMBRIDGE, Mass. – Shares of Bind Therapeutics (BIND) are down more than 64 percent this morning after BIND filed Chapter 11 in the U.S. Bankruptcy Court for the District of Delaware, the company announced this morning. Shares of BIND are trading at 51 cents […]